287 related articles for article (PubMed ID: 27655686)
21. p53 protein expression in chronic lymphocytic leukemia.
Sellmann L; Carpinteiro A; Nückel H; Scholtysik R; Siemer D; Klein-Hipass L; Kube D; Dürig J; Dührsen U; Stanelle J; Küppers R
Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854
[TBL] [Abstract][Full Text] [Related]
22. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
[TBL] [Abstract][Full Text] [Related]
23. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
24. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.
Trachootham D; Zhou Y; Zhang H; Demizu Y; Chen Z; Pelicano H; Chiao PJ; Achanta G; Arlinghaus RB; Liu J; Huang P
Cancer Cell; 2006 Sep; 10(3):241-52. PubMed ID: 16959615
[TBL] [Abstract][Full Text] [Related]
25. Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
Begleiter A; Mowat M; Israels LG; Johnston JB
Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
30. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel O; Wacht N; Sifft E; Melchardt T; Hamacher F; Kocher T; Denk U; Hofbauer JP; Egle A; Scheideler M; Schlederer M; Steurer M; Kenner L; Greil R
Leukemia; 2012 Dec; 26(12):2508-16. PubMed ID: 22743622
[TBL] [Abstract][Full Text] [Related]
31. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
Zenz T; Benner A; Döhner H; Stilgenbauer S
Cell Cycle; 2008 Dec; 7(24):3810-4. PubMed ID: 19098429
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
Agathanggelou A; Weston VJ; Perry T; Davies NJ; Skowronska A; Payne DT; Fossey JS; Oldreive CE; Wei W; Pratt G; Parry H; Oscier D; Coles SJ; Hole PS; Darley RL; McMahon M; Hayes JD; Moss P; Stewart GS; Taylor AM; Stankovic T
Haematologica; 2015 Aug; 100(8):1076-85. PubMed ID: 25840602
[TBL] [Abstract][Full Text] [Related]
33. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
34. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
35. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
36. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
37. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
38. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
39. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
[TBL] [Abstract][Full Text] [Related]
40. PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.
Yeomans A; Lemm E; Wilmore S; Cavell BE; Valle-Argos B; Krysov S; Hidalgo MS; Leonard E; Willis AE; Forconi F; Stevenson FK; Steele AJ; Coldwell MJ; Packham G
Oncotarget; 2016 Nov; 7(46):74807-74819. PubMed ID: 27579538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
